Columbia Daily Tribune
Under a new agreement, the University of Missouri Research Reactor will supply a radioisotope that serves as a key ingredient in a cancer therapy.
The multi-year agreement is with Advanced Accelerator Applications International, a Novartis pharmaceutical manufacturing company.
Since 2017, the research reactor has produced the radioisotope Lutetium-177 for the company under the name Lutathera. It is used to treat some tumors of the gastrointestinal tract and pancreas.
The new version of the radioisotope contains no trace of the long-lived isotope. That s a real benefit because hospitals won t have the same regulations for use, storage and disposal they have with the current version, said David Robertson, research reactor director.
Posted on 407
NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radiopharmaceuticals used for medical imaging and therapeutic treatments, today announced that the U.S. Food and Drug Administration (FDA) has approved its application for producing Mo-99 from concentrated Mo-98 (cMo-98) and related software updates for the RadioGenix® System (technetium Tc 99m generator). Processing of cMo-98 targets increases production capacity of the important medical radioisotope, molybdenum-99 (Mo-99), up to four times above that of current NorthStar technology, and enables NorthStar to provide customers with higher activity source vessels, which will support enhanced radiopharmacy efficiencies. FDA approval was granted through a Prior Approval Supplement (PAS) to NorthStar’s original RadioGenix® System (technetium Tc 99m generator) New Drug Application, which was approved in 2018. The R